CEBPB integrates OSM signaling and eIF4G2-mediated alternative translation to configure enhancer landscape and sustain oncogenic CHI3L1 in glioblastoma

Clicks: 5
ID: 331977
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #261 of 265 articles by views in journal of neuro-oncology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 265 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: CEBPB is a critical driver of mesenchymal transformation and aggressiveness in glioblastoma (GBM). However, fundamental questions remain regarding its dynamic regulation within the GBM microenvironment and its precise mechanistic role in orchestrating the epigenetic and transcriptional reprogramming. METHODS: To decode the CEBPB cistrome and its role in chromatin remodeling in GBM, we performed an integrated analysis of CEBPB/H3K27ac ChIP-seq, CEBPB HiChIP, and RNA-seq. Transcriptional and translational control of CEBPB expression was delineated through enhancer profiling, bioinformatics analysis, siRNA screening, synthetic reporter assays, and immunoblotting. Functional investigations were conducted using patient-derived tumor spheroids, human and murine glioma cell lines, and xenograft/allograft murine models. RESULTS: We demonstrate that CEBPB is a super-enhancer-driven gene, with all three isoforms (LAP1, LAP2, LIP) over-expressed in primary GBM. Functional analyses reveal that LAP1 and LAP2 are essential for tumorigenesis, while LIP specifically promotes in vivo growth in a LAP1/LAP2-dependent manner. We further reveal that myeloid-derived OSM potently induces CEBPB expression through OSMR-STAT3-mediated transcription and a novel eIF4G2-dependent alternative translation process. Mechanistically, eIF4G2 directs selective LIP synthesis by engaging a specialized 3'UTR translation enhancer within the CEBPB transcript. Genetic ablation of EIF4G2 suppresses tumorigenicity, a phenotype fully rescued by LIP overexpression. Ultimately, CEBPB isoforms coordinately rewire the epigenetic landscape, remodeling super-enhancers and chromatin looping to establish an oncogenic transcriptional program that activates key effectors like CHI3L1. CONCLUSIONS: This work elucidates a pathogenic axis in glioblastoma wherein OSM signaling and eIF4G2-mediated alternative translation converge on CEBPB isoforms to enforce enhancer architectures and chromatin interactions for oncogenic transcription.
Reference Key
openalex_W7221071377 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Jiyang Liu, Ying Zhang, Xiaoping Yi, Long Xie, Xingze Huang, Zhipeng Zhu, Zhongyuan Zhang, Jing Wang, Suya Zheng, Yongjie Wang, 珩哲 許, Yue Yu, Zeming Tan, Tuan Zea Tan, H Phillip Koeffler, Ye Chen, Liang Xu
Journal journal of neuro-oncology
Year 2026
DOI
10.1093/neuonc/noag246
URL
https://doi.org/10.1093/neuonc/noag246
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.